Moreover, developing strategies to promote perivascular clearance, such as immunotherapy (271) and to target neurovascular cell-specific mechanisms, including mitochondrial dysfunction (207, 208, 272), to counteract toxicity of both amyloid and tau, will be essential research efforts to ameliorate CVD in AD and other tauopathies. The gene discussed is MAPT; the disease is Alzheimer disease.